|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the EYE 10-Q filed May 10, 2006. VISX
treatment cards. As a result of the VISX Acquisition, the Company became the
leader in the design and development of proprietary technologies and systems
for laser vision correction of refractive vision disorders.
The VISX Acquisition has been accounted for as a purchase business combination. Under the purchase method of accounting, the assets acquired and liabilities assumed are recorded at the date of acquisition at their respective fair values.
9
The following unaudited pro forma information assumes the VISX Acquisition occurred on January 1, 2005. These unaudited pro forma results have been prepared for informational purposes only and do not purport to represent what the results of operations would have been had the VISX Acquisition occurred as of the date indicated, nor of future results of operations. The unaudited pro forma results for the three months ended March 25, 2005 are as follows (in thousands, except per share data):
(1) The unaudited pro forma information for the three months ended March 25, 2005 includes a $7.0 million increase in amortization related to management’s estimate of the fair value of intangible assets acquired as the result of the VISX Acquisition and a $2.8 million increase in interest expense resulting from additional borrowings incurred to fund the cash portion of the VISX Acquisition and related costs and amortization of deferred financing costs.
(2) The weighted average number of shares outstanding used for the computation of basic earnings per share for the three months ended March 25, 2005 reflects the issuance of 27.8 million shares of AMO’s common stock to VISX stockholders.
(3) The weighted average number of shares outstanding used for the computation of diluted earnings per share for the three months ended March 25, 2005 reflects the issuance of 27.8 million shares of AMO’s common stock to VISX shareholders and the dilutive effect of approximately 1.1 million shares of VISX options exchanged for AMO stock options.
This excerpt taken from the EYE 10-K filed Mar 14, 2006. VISX treatment cards.
The VISX Acquisition has been accounted for as a purchase business combination. Under the purchase method of accounting, the assets acquired and liabilities assumed were recorded at the date of acquisition at their respective fair values. Our reported financial position and results of operations after May 27, 2005 include VISX and the impact of purchase accounting. Purchase accounting applied to the VISX Acquisition resulted in a non-cash in-process research and development charge of $488.5 million in the year ended December 31, 2005.
| EXCERPTS ON THIS PAGE:
RELATED TOPICS for EYE: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
